Fondaparinux: A pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome

PharmacoEconomics

Volumn 28, Issue 8, 2010, Pages 687-698

  McKeage, Kate ^a   Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Acute coronary syndromes, treatment; Adis Drug Evaluations; Cost effectiveness; Cost utility; Enoxaparin sodium, therapeutic use; Fondaparinux sodium, therapeutic use; Myocardial infarction, treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALSE ANEURYSM; HEALTH CARE COST; HEMATOMA; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; POLYSACCHARIDES;

EID: 77954532078     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11205130-000000000-00000     Document Type: Review

References (20)

1. Coons JC, Battistone S. 2007 Guideline update for unstable angina/non-ST-segment elevation myocardial infarction: focus on antiplatelet and anticoagulant therapies. Ann Pharmacother 2008 Jul; 42 (7): 989-1001
2. Task Force for the Diagnosis and Treatment of Non-STSegment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28 (13): 1598-1660
3. Hoekstra J, Cohen M. Management of patients with unstable angina/non-ST-elevation myocardial infarction: a critical review of the 2007 ACC/AHA guidelines. Int J Clin Pract 2009 Apr; 63 (4): 642-655
4. European Medicines Agency. Summary of product characteristics. Arixtra 1.5mg/0.3mL solution for injection [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/arixtra/H-403-PI-en.pdf [Accessed 2010 Apr 3]
5. Blick SK, Orman JS, Wagstaff AJ, et al. Fondaparinux sodium: a review of its use in the management of acute coronary syndromes. Am J Cardiovasc Drugs 2008; 8 (2): 113-125
6. Bakhai A, Flather MD, Collinson JR, et al. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation: example from the United Kingdom. Int J Cardiol 2003 Oct; 91 (2-3): 163-172
7. American Heart Association. Heart disease and stroke statistics: 2010 update. Dallas (TX): American Heart Association, 2010
8. British Heart Foundation Statistics Website. Coronary heart disease statistics 2008 [online]. Available from URL: http://www.heartstats.org/ datapage.asp?id=7998 [Accessed 2010 May 6]
9. Etemad LR, McCollam PL. Total first-year costs of acute coronary syndrome in a managed care setting. J Manage Care Pharm 2005; 11 (4): 300-306
10. Access Economics. The economic costs of heart attack and chest pain (acute coronary syndrome) [online]. Available from URL: http://www. accesseconomics.com.au/publica tionsreports/get report.php?report=204&id=262 [Accessed 2010 May 12]
11. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006 Apr 6; 354 (14): 1464-1476
12. MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf F, et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J 2005 Dec; 150 (6): 1107-1110
13. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50 (18): 1742-1751
14. Sculpher MJ, Lozano-Ortega G, Sambrook J, et al. Fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial. Am Heart J 2009 May; 157 (5): 845-852
15. Latour-Perez J, de-Miguel-Balsa E. Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndrome. Pharmacoeconomics 2009; 27 (7): 585-595
16. Sculpher MJ, Lozano-Ortega G, Sambrook JC, et al. Costeffectiveness in France of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome: an analysis using data from OASIS-5 [abstract no. 4804]. Eur Heart J 2007 Sep; 28 Abstr. Suppl.: 858
17. Ramanath VS, Eagle KA. Evidence-based medical therapy of patients with acute coronary syndromes. Am J Cardiovasc Drugs 2007; 7 (2): 95-116
18. Maxwell CB, Holdford DA, Crouch MA, et al. Costeffectiveness analysis of anticoagulation strategies in non- ST-elevation acute coronary syndromes. Ann Pharmacother 2009 Apr; 43 (4): 586-595
19. Carter NJ, McCormack PL, Plosker GL. Enoxaparin: a review of its use in ST-segment elevation myocardial infarction. Drugs 2008; 68 (5): 691-710
20. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96 (9): 1200-1206